Jason Duncan - 28 May 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Title: Chief Legal and Administrative Officer
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Jason Duncan
Issuer symbol
NMRA
Transactions as of
28 May 2025
Net transactions value
$0
Form type
4
Filing time
30 May 2025, 18:30:59 UTC
Previous filing
18 Feb 2025
Next filing
09 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Duncan Jason Title: Chief Legal and Administrative Officer C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN /s/ Michael Milligan, as Attorney-in-Fact for Jason Duncan 30 May 2025 0001741553

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -400,000 -100% 0 28 May 2025 Common Stock 400,000 $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -500,000 -100% 0 28 May 2025 Common Stock 500,000 $1.69 Direct F2, F3
transaction NMRA Stock Option (Right to Buy) Award +400,000 400,000 28 May 2025 Common Stock 400,000 $0.7200 Direct F1, F2, F4
transaction NMRA Stock Option (Right to Buy) Award +500,000 500,000 28 May 2025 Common Stock 500,000 $0.7200 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F2 On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.
F3 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
F4 On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Remarks:

Title: Chief Legal and Administrative Officer